Membrane-type-1 matrix metalloproteinase (MT1-MMP) has transmembrane and cytoplasmic domains, which target it to invasive fronts. We analyzed the role of the cytoplasmic tail by expressing wild type MT1-MMP and three mutants with progressively truncated C termini in human Bowes melanoma cells. We examined gelatinase A activation and the localization and processing of recombinant proteins in stable cell clones using gelatin zymography, immunoblotting, and immunofluorescence. Cell invasion was analyzed in vitro by Matrigel invasion assays. Gelatinase A was activated in all cell clones. However, the localization of MT1-MMP to the leading edge of migrating cells and cell invasion through Matrigel were strongly enhanced only in cells expressing either wild type or truncated MT1-MMP lacking 6 C-terminal amino acid residues (⌬577). Truncations of 10 or 16 amino acid residues in the cytoplasmic domain (⌬567 and ⌬573, respectively) disturbed MT1-MMP localization. The expression of wild type and ⌬577 MT1-MMPs induced also their cleavage to 43-kDa cell surface forms and the release of soluble, ϳ20-kDa N-terminal fragments containing the catalytic center. A synthetic MMP inhibitor but not a gelatinase inhibitor prevented the processing, suggesting that autocatalytic cleavage occurs. Purified soluble MT1-MMP was also autoproteolytically processed to 43-and 20-kDa forms in vitro. Our results indicate that the cytoplasmic domain has an important role in cell invasion by controlling both the targeting and degradation/turnover of MT1-MMP.
The three-step model for tumor cell invasion describes the critical process of cancer metastasis in terms of cell attachment to the extracellular matrix (ECM), 1 localized degradation of the ECM, and cell migration through the digested barrier (1) . A critical balance of protease activation and inhibition at specific cell surface sites is essential for coordinated proteolysis required for cell attachment and invasion. Matrix metalloproteinases (MMPs) and serine proteases are involved in the proteolytic cascades leading to ECM degradation. Recent evidence suggests that MMPs are important also in creating an environment that supports the growth of tumors (2) . MMPs are Zn 2ϩ -dependent endopeptidases, which share a common domain structure. They are produced as inactive proenzymes, and their activation by the proteolytic removal of the N-terminal prodomain is an important control step in ECM degradation. Activated MMPs are inhibited by tissue inhibitors of metalloproteinases (TIMPs). MMPs are expressed in many tumor tissues at higher levels than in normal tissues, and their expression is tightly regulated by growth factors and cytokines (2) .
Membrane-type-1 matrix metalloproteinase (MT1-MMP) is one of the six currently known MT-MMPs (3) (4) (5) (6) (7) (8) . It is expressed in association with gelatinase A (MMP-2) in various human malignant tumors, including colon, breast, gastric, head and neck, lung, and cervical carcinomas (9) . MT-MMPs differ from all other MMPs in that they have hydrophophic transmembrane domains and short cytoplasmic tails. In addition, they contain recognition sites for the furin-like proprotein convertases between their pro and catalytic domains. Therefore, they appear to be constitutively activated by these proteases (10) . The structure of the human MT1-MMP/MMP-14 gene differs from the other MMP genes in exon organization, suggesting a relatively early divergence in evolution (11) .
Until recently, the primary function assigned to MT-MMPs has been the binding and processing of secreted progelatinase A to its active form. The activation depends on the formation of a ternary complex between MT1-MMP, TIMP-2, and gelatinase A and initial cleavage of gelatinase A prodomain by another MT1-MMP molecule (12) (13) (14) (15) . MT1-MMP can also activate procollagenase-3 (MMP-13) (16) . MT1-MMP expression levels in tumor tissues correlate with gelatinase A activation levels, and the malignancy and invasiveness of the tumor, supporting the proposed function as gelatinase A activator (17) . MT1-MMP is abundantly expressed by highly invasive melanoma cells in vivo, whereas gelatinase A and TIMP-2 are detected in stromal cells bordering tumors (18) . MT1-MMP itself is also a potent matrix-degrading protease with broad collagenolytic, glycoproteolytic, and gelatinolytic activities (19, 20) . In addition, it is a very efficient fibrinolytic protease (21) , and collagen turnover in MT1-MMP-deficient mice was severely compromised (22) .
MT1-MMP appears to have an important role in promoting cell migration through the ECM. MT1-MMP overexpression in HT-1080 cells enhances the rate of cell migration through a Matrigel (Becton Dickinson, Mountain View, CA) barrier (3) . In addition, MT1-MMP overexpression in melanoma cells in-creases the degradation rate of fibronectin-coated, cross-linked gelatin films (23) . The cytoplasmic and transmembrane domains of MT1-MMP are important for the localization of MT1-MMP to the sites of matrix degradation and for the cellular invasion. Active gelatinase A is partially localized to the same sites, thus generating a restricted pericellular environment for ECM degradation (23) . During gelatinase A activation MT1-MMP is processed by an MMP-dependent mechanism to its 43-kDa form, which lacks most of the catalytic domain (24, 25) . The present study was carried out to characterize the role of the cytoplasmic domain for targeting MT1-MMP activities using human Bowes melanoma cells and site-directed mutagenesis. We found that the middle part of the MT1-MMP cytoplasmic domain was essential for the correct localization of MT1-MMP to the leading edges of migrating cells. Focusing of MT1-MMP activity enhanced the invasive potential of Bowes melanoma cells and caused an autocatalytic cleavage of MT1-MMP to cell-bound 43-kDa and soluble 20-kDa fragments.
EXPERIMENTAL PROCEDURES
Reagents-Thermostable AmpliTag polymerase was from PerkinElmer (Branschburg, NJ), and Pfu polymerase was from Stratagene (La Jolla, CA). All the DNA-modifying enzymes were purchased from New England Biolabs (Beverly, MA). pcDNA3 eukaryotic expression vector was from InVitrogen (Oxford, UK). Reagents for dideoxy sequencing were from Amersham Pharmacia Biotech. Cyclic peptide inhibitor CTTHWGFTLC, which inhibits specifically gelatinases A and B (26), was obtained from Dr. E. Koivunen (Department of Biochemistry, University of Helsinki). The general inhibitor of metalloproteinase activity, BB-3103, was a generous gift from British Biotech Pharmaceuticals Ltd. (Oxford, UK).
Cell Culture-Human Bowes melanoma cells were selected for the invasion and activity studies in the MT1-MMP overexpression system, because they have low endogenous expression levels of MT1-MMP, TIMPs, and other MMPs as compared with several other melanoma cells and they produce low levels of gelatinase A, which remains latent even in the presence of phorbol 12-myristate 13-acetate (18) . Cells were cultivated in Eagle's minimal essential medium (MEM) containing 10% heat-inactivated fetal calf serum (Life Technologies, Inc., Gaithersburg, MD), 100 IU/ml penicillin, and 50 g/ml streptomycin. The cultures were incubated at 37°C in humidified 5% CO 2 atmosphere until confluency. All experiments were carried out in serum-free conditions. For the collection of conditioned medium and cell lysates, the cultures were rinsed twice with serum-free medium, incubated under serum-free conditions for 6 h, and rinsed again with serum-free medium. The conditioned medium was then collected after 24 h. The cells were lysed on ice with Triton lysis buffer (50 mM Tris-HCl buffer, pH 8.0, containing 150 mM NaCl, 1% Triton X-100, 0.02% sodium azide, 10 mM EDTA, 10 g/ml aprotinin, 1 g/ml pepstatin A, and 1 g/ml aminoethylbenzene sulfonyl fluoride; Calbiochem, San Diego, CA). The lysates were clarified by centrifugation.
cDNA Constructs-The cloning of bases 1-2369 of MT-MMP-1 cDNA as an EcoRI fragment to pcDNA3 eukaryotic expression vector (MTpc3SE) has been described (25) . Segments of MT1-MMP cDNA (bases 1418 -1820, 1418 -1835, and 1418 -1848) were amplified using polymerase chain reaction (PCR) with oligonucleotides containing a TGA-stop codon and the XbaI restriction endonuclease recognition site at the 3Ј-end. Subsequently, the fragments were cloned as BsmBI-XbaI fragments to MTpc3SE, thus generating the constructs ⌬577, ⌬573, and ⌬567. The wt construct containing the whole open reading frame of MT1-MMP was made by amplifying by PCR a segment containing bases 1418 -1906 of MT1-MMP cDNA and a XbaI recognition site at the 3Ј-end and cloning it as a BsmBI-XbaI fragment to MTpc3SE. The difference between construct E240A and wt is that the codon GAG coding for E240 was mutated to the alanine codon GCG by PCRmediated mutagenesis using two partially overlapping oligonucleotides. This point mutation inactivates the enzyme (27) . For the ⌬TM construct, a segment containing bases 1482-1733 was amplified by PCR with oligonucleotides containing a TGA-stop codon, six additional histidine codons (CAC), and the EcoRI restriction endonuclease recognition site at the 3Ј-end. The PCR segment was digested with BamHI and ligated with a 1490-base pair (bp) EcoRI-BamHI fragment of MTpc3SE. The generated EcoRI fragment was then cloned to the MTpc3SE. The constructed deletion and point mutations are illustrated in Fig. 1 . All the constructs were verified by automated sequencing using ABI 310 (Perkin-Elmer, Norwalk, CT).
Expression of Recombinant MT1-MMP Proteins in Bowes CellsCells were cultured in 6-well plates to reach 50 -80% confluence and transfected using 2 g of plasmid DNA and 5 l of FuGENE 6 transfection reagent for each transfection according to the manufacturer's instructions (Roche Molecular Biochemicals, Mannheim, Germany). Transfection mixture was applied onto cells in the presence of serum and antibiotics, and the incubation was carried out for 6 h. The cells were then washed twice with serum-free MEM. After 48 h the cells were fixed for immunofluorescence staining, or the selection for stable transfectants was started with 1.2 mg/ml G418 (Life Technologies, Inc.) in complete medium.
Expression of the recombinant MT1-MMPs by transfected cell clones was analyzed by Northern hybridization and immunoblotting. Cell clones producing about 10-fold excess of wild type or mutated MT1-MMP as compared with endogenous expression level of MT1-MMP were selected for the experiments.
Antibodies-Polyclonal antibodies to MT1-MMP were raised in rabbits. The immunogens used were (illustrated in Fig. 1 ): a bacterially generated recombinant fusion protein of Schistosoma japonicum glutathione S-transferase and amino acid residues 260 -484 of MT1-MMP (Ab-1), a synthetic peptide of 26 amino acid residues corresponding to the C-terminal intracellular domain of MT1-MMP (Ab-2), and a synthetic peptide of 24 amino acid residues corresponding to amino acids 154 -167 of MT1-MMP (Ab-3). The antibodies were affinity-purified using the respective immunogens coupled to Sepharose 4B (25) .
SDS-PAGE and Immunoblotting-SDS-polyacrylamide gel electrophoresis (PAGE) was carried out using 4 -15% gradient or 10% standard Laemmli polyacrylamide gels (Bio-Rad, Richmond, VA). Proteins were electrophoretically transferred to nitrocellulose membranes (Gelman Sciences, Ann Arbor, MI). Immunodetection of the proteins was performed as described (25) .
Gelatin Zymography-To analyze the gelatinolytic proteins, aliquots of cell-conditioned medium were analyzed by zymography essentially as described previously (28) .
Immunofluorescence-Bowes cells were cultured to ϳ80% confluence and transfected with MT1-MMP constructs as described, or the cell clones were cultured to 100% or ϳ20% confluence on glass coverslips. For the staining of migrating cells, a gel containing serum-free MEM and 0.5% low melting point agar was poured above the cells. Chemoattractant gradient was generated to the solid agar gel by adding 1 ng of fibroblast growth factor-2 or 5 l of fetal calf serum to one side of the coverslips (29) . After 24 h the gel was removed by suction, and the cells were washed with serum-free MEM and fixed with 3% paraformaldehyde. For intracellular staining, the cells were permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBS) for 20 min. Subsequently, the coverslips were treated with 5% bovine serum albumin in PBS for 30 min, washed twice with PBS containing 0.5% bovine serum albumin and incubated with affinity-purified polyclonal Ab-1 (see Fig.  1 ) for 1 h. The coverslips were then washed three times and incubated with fluorescein isothiocyanate-conjugated anti-rabbit antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h. Next, the coverslips were washed four times and mounted on glass slides using Vectashield (Vector Laboratories, Burlingame, CA). The fluorescence images were obtained by using an epifluorescence microscope or a Bio-Rad MRC-1024 confocal microscope.
In Vitro Invasion Assay-The Boyden chamber cell invasion assay was carried out according to manufacturer's instructions (Becton Dickinson). Bowes control cells or stably transfected Bowes cells expressing wild type or mutated MT1-MMP proteins (1 ϫ 10 5 cells/ml) were suspended in MEM containing 0.1% bovine serum albumin and seeded onto uncoated or Matrigel-coated Transwell filters (8-m pore size) in Biocoat Matrigel invasion chambers. Proteinase inhibitors aprotinin (100 g/ml), BB-3103 (10 M), or peptide inhibitor CTTHWGFTLC (500 nM) were added to the suspension of control cells or cells expressing wt MT1-MMP, and the cells were seeded onto the filters after 0.5 h of incubation. Fetal calf serum (5%) was used as a chemoattractant in the lower chambers. After 18 h of incubation, noninvading cells were removed from the top surface of the filter, and the filters were stained with Diff-Quik (Dade AG, Dudingen, Switzerland). Cells migrated onto the lower surface of the filter were counted under a microscope at ϫ 40 or ϫ 200 magnification. Each assay was carried out in triplicate, and five fields were counted.
In Vitro Analyses of MT1-MMP Cleavage-Recombinant soluble forms of wild type and inactive MT1-MMP (⌬TM and E240A⌬TM, respectively) were expressed in a baculovirus/insect cell system and purified by cation exchange and gel filtration chromatography (27) . ⌬TM and E240A⌬TM (10 ng) were incubated alone or with proteinase inhibitors as indicated in 50 mM Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl, 10 mM CaCl 2 , 0.05% Brij 35, and 0.02% NaN 3 at 37°C for 3 h. The reactions were terminated with reducing Laemmli sample buffer, and the MT1-MMP fragments were separated by SDS-PAGE and characterized by immunoblotting.
RESULTS

Expression of MT1-MMP Mutants and
Gelatinase A Activation-To examine the effects of the cytoplasmic domain of MT1-MMP on its own protein expression, gelatinase A activation, and cell invasion, we prepared three MT1-MMP constructs encoding proteins with deletions in the cytoplasmic domain. The C-terminal fragments containing amino acids from Ser 577 , Tyr 573 , or Thr 567 to Val 582 were eliminated from the mutated MT1-MMP proteins designated as ⌬577, ⌬573, and ⌬567, respectively (Fig. 1) . Wild type MT1-MMP (wt); soluble truncated MT1-MMP, lacking the transmembrane and cytoplasmic domains (⌬TM); and inactive MT1-MMP, containing point mutation E240A, were used as controls. The constructs were transfected to human Bowes melanoma cells, and stable cell clones were generated by G418 selection and dilution cloning. Positive cell clones were selected by immunoblotting. Two separate cell clones expressing each of the deletion mutants ⌬577, ⌬573, and ⌬567, and one cell clone expressing each control protein, were used in the experiments. Northern blotting indicated that all clones had 8-to 10-fold overexpression of wt or mutated MT1-MMP mRNA, as compared with endogenous MT1-MMP expression levels (data not shown). Northern hybridization was used also to detect possible changes in the expression levels of mRNAs for TIMP-2, ␣ V and ␤ 3 integrins, urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor by the cell clones. No significant differences, which could affect gelatinase A activity and cell invasion, were found. Bowes cells did not express detectable levels of mRNA for MMP-13, whose activation could also be affected by MT1-MMP (data not shown). By immunoblotting, using polyclonal Ab-3 against the N-terminal part of the MT1-MMP catalytic domain, MT1-MMP was detected as 60-and 63-kDa protein bands corresponding to its active and proenzyme forms, respectively ( Fig. 2 ; characterized in detail in Ref. 24) . Increased levels of the 60-and 63-kDa forms were detected in all transfected cells. Expression of ⌬567 caused the appearance of an additional immunoreactive band of ϳ58 kDa and occasionally an additional band of 35-40 kDa. The identities of these bands were not analyzed further.
Overexpression of MT1-MMP induces gelatinase A activation (3). To examine the effects of the cytoplasmic domain deletions of MT1-MMP on gelatinase A activation, aliquots of the conditioned media of Bowes cell clones were analyzed by gelatin zymography. Nontransfected cells as well as cloned cells expressing wt, E240A, and ⌬TM were used as controls. Gelatinase A was processed to its activated 64-and 62-kDa forms by all cell clones expressing wild type MT1-MMP or mutants containing a deletion in the cytoplasmic domain (⌬577, ⌬573, and ⌬567) (Fig. 2) . Cells expressing either soluble ⌬TM or the inactive E240A were unable to activate gelatinase A. However, low levels of the intermediate forms were observable also in these cells.
Cell Surface Localization of MT1-MMP-To confirm the specificities of the antibodies in immunofluorescence staining and to analyze the localization of the proteins encoded by the wt, ⌬TM, E240A, ⌬577, ⌬573, and ⌬567 constructs, we first carried out transient transfections of Bowes cells cultured on glass coverslips. The cells were fixed and subjected to immunofluorescence staining using affinity-purified Ab-1 against hinge/pexin-like domains of MT1-MMP. Comparison of the phase contrast and fluorescence images indicated that 5-10% of the cells were positive when stained with the MT1-MMP antibodies (Fig. 3A) . The endogenous expression of MT1-MMP was not sufficient to generate specific detectable staining in the rest of the cells. In cells transfected with either wt, E240A, ⌬577, ⌬573, or ⌬567 plasmids, the protein products were localized to the cell surface as found in wt transfectants (Fig. 3A) , whereas in cells transfected with ⌬TM only intracellular staining was observed (Fig. 3A) . wt, E240A, ⌬577, ⌬573, and ⌬567 proteins were also accessible to cell surface biotinylation (data not shown) as observed earlier for wild type MT1-MMP in HT-1080 cells (24) .
The cell surface localization of MT1-MMP was examined next by immunofluorescence staining of cloned Bowes cells expressing the wt, E240A, ⌬577, ⌬573, and ⌬567 forms of MT1-MMP. No specific staining was detected in nontransfected control cells (Fig. 3B) . In confluent cell cultures all the recombinant MT1-MMPs containing transmembrane domains were spread around the plasma membranes similarly with wt (Fig.  3B) . In sparse cultures, part of the cells had a random migrating phenotype, and in those cells the full length recombinant MT1-MMPs (wt and E240A) were concentrated to special membrane sites as those seen in Bowes cell clone expressing wt (Fig.  3B) . To characterize the effects of cytoplasmic deletions on the MT1-MMP localization in migrating cells, we cultured the cells in a chemotactic gradient and analyzed the MT1-MMP staining with confocal microscopy. Optical section images focused from the matrix contact to the top of the cells indicated that the wild type MT1-MMP as well as the ⌬577 proteins were concentrated at the leading edges of the cells at the substratum contact level (Fig. 4) . On the contrary, the shorter forms ⌬573 and ⌬567 were distributed more equally around the plasma membranes from the bottom to the top of the cells.
Enhanced Invasion of the Bowes Melanoma Cells-To analyze the effects of expression of wild type MT1-MMP or the mutants on the ability of Bowes melanoma cells to invade through basement membranes, we carried out Boyden chamber cell invasion assays. Cell invasion in vitro through basement membrane matrices was strongly enhanced by the expression of either the wild type MT1-MMP or ⌬577 lacking 6 C-terminal amino acids (Fig. 5A) . Invasion was also appreciably enhanced by the expression of truncated MT1-MMP lacking 10 C-terminal amino acids (⌬573). On the contrary, the expression of ⌬567 lacking 16 C-terminal amino acids, soluble truncated (⌬TM), or the inactive MT1-MMP (E240A) did not significantly enhance cell invasion.
We analyzed next the inhibition of invasion by three proteinase inhibitors: a broad spectrum MMP inhibitor BB-3103; the cyclic peptide CTTHWGFTLC (26) that is inhibitory for gela- 1 ) were cultured on glass coverslips. Gel containing serum-free medium and 0.5% agar was poured above the cells. Chemoattractant gradient was generated to the solid agar gel by adding 1 ng of fibroblast growth factor-2 or 5 l of fetal calf serum to one side of the coverslips. After 24 h, the gel was removed, and the cells were fixed with 3% paraformaldehyde and immunostained with Ab-1. MT1-MMP staining was analyzed by obtaining a series of optical section images with confocal microscopy. Images focused to the matrix contact level are shown.
tinase A and B activities, but does not inhibit MT1-MMP; and aprotinin. The invasion of control cells was only moderately affected by the inhibitors (Fig. 5B) . In contrast, the invasion of cells expressing wt MT1-MMP was decreased to the level of control cells by BB-3103. The cyclic peptide CTTHWGFTLC inhibited the invasion of MT1-MMP overexpressing cells by about 56%. However, there was still a clear difference in the invasion rate as compared with the control cells. Aprotinin had only a moderate inhibitory effect.
Inactivation of MT1-MMP by Autocatalytic Cleavage of a 20-kDa Soluble Fragment-Gelatinase
A activation in fibrosarcoma cells is accompanied by the N-terminal processing of MT1-MMP to its inactive 43-kDa form by an MMP-dependent mechanism (24, 25) . Accordingly, immunoblotting analyses with Ab-1 against hinge/pexin-like domains of MT1-MMP revealed the appearance of the 43-kDa form also in Bowes melanoma cells (Fig. 6A) . The levels of the 60-kDa active and 63-kDa latent forms of MT1-MMP in cell lysates correlated with the detection of these forms with Ab-3 (Fig. 2) . Expression of wt MT1-MMP and ⌬577, and to some extent ⌬573, also induced the appearance of 43-kDa form. In cells expressing ⌬567 with the shortest cytoplasmic tail or the E240A inactive mutant, the 43-kDa form was not observed. The level of the 43-kDa form was notably lower in the cells expressing ⌬573 than in cells expressing ⌬577 or wt MT1-MMP.
To further characterize the cleavage cascade and to detect the cleaved N-terminal fragment(s), aliquots of Bowes cellconditioned media were analyzed by immunoblotting using 1 ) were washed and incubated with serum-free MEM. Conditioned media were collected, and the cells were lysed. Proteins of cell lysates were separated by SDS-PAGE using 4 -15% gradient gels under reducing conditions. The proteins were transferred onto nitrocellulose and immunostained for MT1-MMP protein using Ab-1 against hinge/pexinlike domains of MT1-MMP. B, immunoblotting of conditioned media was done using Ab-3 against a synthetic peptide corresponding to 24 amino acids in the catalytic domain of MT1-MMP (Ab-3). C, confluent cultures of Bowes cells expressing wt MT1-MMP were washed and incubated under serum-free conditions for 24 h with MMP inhibitors as indicated. Subsequently, the cells were lysed, and the lysates were subjected to immunoblotting using Ab-1 as above. Migration of the different immunoreactive MT1-MMP protein bands is indicated on the right (63, 60, 56, and 20) , and the molecular mass markers are indicated on the left. Note the enhanced levels of MT1-MMP protein in the medium of ⌬TM cells and the generation and release into the soluble phase of the 20-kDa fragment of MT1-MMP (arrowhead) in cells expressing wt, ⌬TM, and ⌬577.
Ab-3 against a synthetic peptide corresponding to 24 amino acids in the catalytic domain of MT1-MMP. Immunoblotting analysis revealed a soluble ϳ56-kDa form of MT1-MMP in cells expressing either the wild type MT1-MMP or one of the mutants with a truncated cytoplasmic domain (⌬567, ⌬573, ⌬577). Those proteins comigrated with the 56-kDa soluble truncated MT1-MMP lacking the transmembrane and cytoplasmic domains (⌬TM) (Fig. 6B) . In addition, the expression of wt, ⌬TM, and ⌬577 resulted in the appearance of a soluble cleavage product of ϳ20 kDa (Fig. 6B ). An additional immunoreactive band of 35-40 kDa (evidently cleaved at the pexin-like domain because it was detected by Ab-3) was observed in the medium of cells expressing ⌬TM. On the contrary, cells expressing the inactive E240A did not secrete any soluble forms. Conditioned media were analyzed next by immunoblotting using Ab-2 against the cytoplasmic domain of MT1-MMP. No immunoreactive proteins were detected with these antibodies (data not shown) indicating that the soluble 56-kDa forms detected with Ab-3 lack the cytoplasmic domain.
To analyze whether MT1-MMP is processed to its 43-kDa form by gelatinase A, confluent cultures of Bowes cells overexpressing wild type MT1-MMP were cultured in the presence of the gelatinase-specific inhibitor, the cyclic peptide CTTHWG-FTLC (26) . The MMP inhibitor BB-3103 that inhibits all MMP activity was used as a control. After 24 h of incubation, the cells were lysed and analyzed by immunoblotting with Ab-1. BB-3103 completely prevented processing to the 43-kDa form at concentrations higher than 300 nM (Fig. 6C) . In addition, the levels of the 60-kDa form were increased. On the contrary, the gelatinase-specific inhibitor did not affect the processing of MT1-MMP, even at high concentrations (500 nM).
We analyzed next the autocatalytic activity of MT1-MMP using recombinant soluble forms of wild type and inactive MT1-MMP (⌬TM and E240A⌬TM, respectively). Both purified recombinant proteins migrate in SDS-PAGE as a single 56-kDa band, corresponding to the furin-activated forms lacking the prodomain (27) . Incubation of purified ⌬TM protein alone at 37°C for 3 h resulted in the appearance of a 43-kDa form that was immunoreactive with Ab-1 against hinge/pexin-like domains of MT1-MMP (Fig. 7) . The 43-kDa form was not detected with Ab-3 against the N-terminal part of the catalytic domain (Fig. 7) . Minor ⌬TM fragments of about 50 and 36 kDa were detectable with Ab-1 and Ab-3. In addition, three fragments of ⌬TM with molecular weights from 16 to 30 kDa were detectable with Ab-3. BB-3103 prevented the processing, whereas the cyclic peptide CTTHWGFTLC had no effect on the appearance of the fragments. No processing of the E240A⌬TM protein was detected (Fig. 7, right panel) . DISCUSSION MT1-MMP is an effective ECM-degrading protease, and in a complex with TIMP-2 it works as a receptor and activator for gelatinase A. It may also interact with other MMP activation cascades (30) . This implies that the localization of MT1-MMP to specific sites at the cell surface can regulate pericellular proteolysis very efficiently by concentrating proteolytic activities in the vicinity of the cell surface. In this study we designed MT1-MMP proteins with mutations in the cytoplasmic domain and expressed them in human Bowes melanoma cells. We analyzed the effects of the mutations on the targeting of MT1-MMP activity. The results indicated that, as a consequence of shortening the cytoplasmic tail, the localization, the invasive functions, and the turnover of MT1-MMP were affected. However, overexpression of recombinant membrane-associated forms of MT1-MMP induced gelatinase A activation regardless of C-terminal deletions.
In contrast to wild type MT1-MMP soluble MT1-MMP, lacking the transmembrane and cytoplasmic domains, and chimeric MT1-MMP, containing the interleukin 2 receptor ␣ chain, transmembrane and cytoplasmic domains are unable to localize to specialized cell surface protrusions called invadopodia or to induce invasion of RPMI7951 melanoma cells (23) . Our results suggest that the amino acid residues between Thr 567 and Ser 577 in the middle part of the MT1-MMP cytoplasmic domain are essential for the regulation of the MT1-MMP localization and for the function of MT1-MMP in Bowes cell invasion through Matrigel. Immunofluorescence analyses indicated that in migrating Bowes cells wild type MT1-MMP and ⌬577 (lacking 6 C-terminal amino acids) were localized to the leading edges of the cells, whereas ⌬573 and ⌬567, lacking 10 and 16 amino acids, respectively, were spread throughout the membranes. In confluent cultures, all the recombinant MT1-MMPs that contain transmembrane domains remained spread around the plasma membranes, probably because the cells were in close contact with each other and had no space to migrate. At the molecular level, gelatinase A activation supposedly requires two adjacent MT1-MMP molecules, one of which functions as a receptor and another as an activator. Therefore, the focal concentration of MT1-MMP is a regulatory factor for gelatinase A activation. Increased focal concentration of MT1-MMP can result from increased MT1-MMP expression or its localization to specific sites at the membranes. Gelatinase A activation was induced in Bowes cell clones by overexpression of any one of the membrane-associated catalytically active forms of MT1-MMP, and no regulation at the level of MT1-MMP localization was required for the activation. However, the gelatinase A activation as such, without the correct localization of MT1-MMP, was not sufficient to enhance Bowes cell invasion through Matrigel. These results suggest that gelatinase A activity had to be accumulated to specific sites at cell surface by MT1-MMP to enhance cell invasion. In addition, the gelatinase-specific inhibitory peptide CTTHWGFTLC was not as effective on inhibiting invasion of MT1-MMP overexpressing cells as BB-3103, suggesting that gelatinase A-independent MT1-MMP activity was involved in Bowes cell invasion. Chen and Wang (31) have demonstrated that, in the invadopodial membrane sites at the cellular periphery, MT1-MMP and gelatinase A are restricted from inhibition by TIMPs, in contrast to the proteinases at membrane sites that are accessible to soluble inhibitors. Targeting of MT1-MMP and gelatinase A to the invasion sites at the surface of Bowes cells may similarly FIG. 7 . Autoproteolytic processing of soluble MT1-MMP. Recombinant soluble forms of wild type and inactive MT1-MMP (⌬TM and E240A⌬TM, respectively) were incubated alone or either with the gelatinase-specific peptide inhibitor CTTHWGFTLC (500 nM), or with the broad-spectrum MMP inhibitor BB-3103 (1 M) at 37°C for 3 h. The reactions were terminated by addition of reducing Laemmli sample buffer. The MT1-MMP fragments were separated by SDS-PAGE and analyzed by immunoblotting using Ab-1 or Ab-3 as indicated.
prevent their inhibition by TIMPs and induce local degradation of Matrigel.
Cultivation of cells in three-dimensional type I collagen induces gelatinase A activation by MT1-MMP in different cell types, and gelatinase A activation by fibrosarcoma cells is promoted by culturing on fibronectin (32) (33) (34) (35) (36) . Those activation mechanisms have been suggested to involve signaling through integrins and intracellular signal transduction molecules or cytoskeletal changes. Hypothetically, interactions of MT1-MMP with cytoskeletal proteins in focal contact complexes or aggregation with integrins can modulate the MT1-MMP localization (37) . The role of integrins in collagen type I-induced gelatinase A activation is currently unclear, and no direct interactions of the cytoplasmic domain of MT1-MMP with other proteins have been characterized. Interestingly, there are three putative phosphorylation sites in the intracellular tail of MT1-MMP: Ser 577 , Tyr 573 , and Thr
567
. All these three amino acids were included in the 16 amino acids, two of them in the 10 amino acids and one in the 6 amino acids deleted from ⌬567, ⌬573, and ⌬577, respectively. The ⌬577 lacking Ser 577 had an equal effect with wild type MT1-MMP on localization, but the possible phosphorylation of Thr 567 or Tyr 573 might participate in the regulation of the cytoplasmic interactions and localization of MT1-MMP. We also made constructs encoding proteins with point mutations of Thr 567 and Tyr 573 to alanine. However, the synthetic peptide Ab-2 against the cytoplasmic domain no longer recognized these proteins, probably because the conformations of the cytoplasmic domains were altered (data not shown). We were therefore unable to draw any conclusions from the behavior of those proteins. Possible phosphorylation changes of MT1-MMP were not analyzed in the current work.
The cytoplasmic domain of MT1-MMP has a C-terminal valine that has been suggested to affect the activation of MT1-MMP and its transport to the plasma membrane (38) . MT1-MMP with mutation of Val 582 to glycine has been reported to be retained in the endoplasmic reticulum. However, ⌬567, ⌬573, and ⌬577, all lacking the C-terminal valines, were transported to the cell surface, and we observed no accumulation of the 63-kDa proenzyme or glycosylated 80-to 84-kDa forms, as was reported by Urena et al. (38) . Expression of ⌬567 caused the appearance of additional proteins of ϳ58 kDa and 35-40 kDa, which could indicate some problems in the folding of this protein or its partial degradation. However, the relative levels of the 63-and 60-kDa forms of ⌬567 were similar to those of the overexpressed wild type MT1-MMP.
Proteolytic processing of MT1-MMP to the inactive 43-kDa form correlates with gelatinase A activation in fibrosarcoma cells (24, 36) . Here we found that wild type MT1-MMP and ⌬577 were cleaved to a soluble 20-kDa fragment and to the inactive 43-kDa cell surface form. The 20-kDa fragment was recognized by Ab-3 against the N-terminal region of the catalytic domain. The inactive 43-kDa form with N-terminal Ala 255 is processed directly from the activated MT1-MMP with Nterminal Tyr 112 (24) . The 20-kDa fragment corresponds, therefore, most probably to the sequence between Tyr 112 and Ala 255 , which contains most of the catalytic domain. Its calculated molecular mass is 14.5 kDa. Zymographic analyses of the concentrated conditioned media did not reveal any low molecular mass gelatinolytic bands corresponding to the 20-kDa fragment (data not shown), indicating that no gelatinolytic activity of MT1-MMP was retained after the cleavage. However, some soluble active MT1-MMP of about 56 kDa and lacking the cytoplasmic domain, was shed from Bowes cell clones that expressed wild type MT1-MMP or the forms with mutation in the cytoplasmic domain.
At least soluble MT1-MMP, gelatinase A, MMP-3, and MMP-13 can process membrane-bound MT1-MMP to the inactive form In vitro (36) . In addition, synthetic metalloproteinase inhibitors and TIMP-2 inhibit the processing in fibrosarcoma cells, whereas TIMP-1, which is a poor inhibitor of MT1-MMP (39), has no effect on processing. We found that the E240A point mutation in the catalytic domain of MT1-MMP prevented the inactivating cleavage as well as the shedding of the 56-kDa form. These results suggest that MT1-MMP is involved in the processing, either directly or through activation of another proteinase. Bowes cells do not express MMP-13. Activated gelatinase A and MT1-MMP itself are therefore the best candidate proteases responsible for the cleavage. However, the gelatinase-specific inhibitory peptide (26) did not prevent MT1-MMP processing in Bowes cells, suggesting that gelatinase A is not involved in MT1-MMP inactivation. In vitro experiments with recombinant soluble forms of wild type and E240A MT1-MMP confirmed that catalytically active MT1-MMP was able to cause the cleavage. Inactivating mutation and the BB-3103 metalloproteinase inhibitor also prevented the autocatalytic processing of soluble MT1-MMP in vitro. The gelatinase-specific inhibitory peptide had no effect on the processing. Based on these results we propose that, at the sites of high focal activities, a putative mechanism for negative regulation of MT1-MMP activity is its own autocatalytic inactivating cleavage.
